

PRODUCT INFORMATION




Elbasvir

Item No. 24031

CAS Registry No.: 1370468-36-2
Formal Name: N,N'-[[[(6S)-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediy]]]]bis-carbamic acid, C,C'-dimethyl ester

Synonym: MK-8742
MF: C₄₉H₅₅N₉O₇
FW: 882.0
Purity: ≥98%
UV/Vis.: λ_{max}: 284, 352, 369 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Elbasvir is supplied as a crystalline solid. A stock solution may be made by dissolving the elbasvir in the solvent of choice, which should be purged with an inert gas. Elbasvir is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of elbasvir in ethanol and DMF is approximately 33 mg/ml and approximately 20 mg/ml in DMSO.

Elbasvir is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, elbasvir should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Elbasvir has a solubility of approximately 0.33 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A) with an EC₅₀ value of 2.2 pM in Huh7 human liver cancer cells expressing pH77S.3/GLuc2A, a cell-culture adapted HCV16 genotype 1a derivative and luciferase reporter, following a 48-hour exposure *in vitro*.^{1,2} NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM.² It exhibits potent inhibitory activity against a broad range of HCV genotypes with EC₅₀ values of 0.0002 to 34 nM in Huh7 cells expressing replicons of HCV genotype 4 NS5A and EC₅₀ values of less than 0.2 nM for replicons from all other tested genotypes except 2b.^{1,3,4} Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV.

References

1. Lahser, F.C., Bystol, K., Curry, S., *et al.* *Antimicrob. Agents Chemother.* **60**(5), 2954-2964 (2016).
2. McGivern, D.R., Masaki, T., Williford, S., *et al.* *Gastroenterology* **147**(2), 453-462 (2014).
3. Asante-Appiah, E., Curry, S., McMonagle, P., *et al.* *Antimicrob. Agents Chemother.* **61**(7), e00363-e00417 (2017).
4. Liu, R., Curry, S., McMonagle, P., *et al.* *Antimicrob. Agents Chemother.* **59**(11), 6922-6929 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/16/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM